Serum uric acid: A new therapeutic target for nonalcoholic fatty liver disease

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 3, 2016, Pages 375-387

  Sun, Dan Qin ^a   Wu, Sheng Jie ^b   Liu, Wen Yue ^b   Lu, Qian Di ^a   Zhu, Gui Qi ^b,c   Shi, Ke Qing ^b,c   Braddock, Martin ^d   Song, Dan ^a   Zheng, Ming Hua ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d ASTRAZENECA   (United Kingdom)

Author keywords

inflammasomes; insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; serum uric acid; therapeutic options

Indexed keywords

ALLOPURINOL; ARHALOFENATE; BENZBROMARONE; FEBUXOSTAT; INFLAMMASOME; LESINURAD; PEGLOTICASE; PROBENECID; SULFINPYRAZONE; TOPIROXOSTAT; ULODESINE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

DRUG TARGETING; EPIDEMIC; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; THERAPY EFFECT; URIC ACID BLOOD LEVEL; ANIMAL; BLOOD; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

ANIMALS; DRUG DESIGN; HUMANS; HYPERURICEMIA; INFLAMMASOMES; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; URIC ACID;

EID: 84958036499     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1096930     Document Type: Review

References (84)

1. Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: A common manifestation of a metabolic disorder. QJM : monthly journal of the Association of Physicians 2003;96(10):699-709
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-31
3. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22(6):788-93
4. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol 2008;48(Suppl 1):S104-12
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363(14):1341-50
6. Day CP, James OF. Steatohepatitis: A tale of two "hits?" Gastroenterology 1998;114(4):842-5
7. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010;52(5):1836-46
8. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55(10):1293-301
9. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circulation journal : official journal of the Japanese Circulation Society 2005;69(8):928-33
10. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. Journal of the Chinese Medical Association : JCMA 2006;69(11):512-16
11. Liang J, Pei Y, Gong Y, et al. Serum uric acid and non-alcoholic fatty liver disease in non-hypertensive Chinese adults: The Cardiometabolic Risk in Chinese (CRC) study. Eur Rev Med Pharmacol Sci 2015;19(2):305-11
12. Sertoglu E, Ercin CN, Celebi G, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 2014;47(6):383-8
13. Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013;62(3):392-9
14. Xie Y, Wang M, Zhang Y, et al. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PloS One 2013;8(7):e67152
15. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-5
16. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) 2009;33(1):54-66
17. Hanley AJ, Festa A, D'Agostino RB Jr, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004;53(7):1773-81
18. Haring R, Rosvall M, Volker U, et al. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PloS One 2012;7(6):e39461
19. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother 2011;12(12):1887-900
20. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol WJG 2013;19(22):3375-84
21. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37(4):917-23
22. Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015;5(1):51-68
23. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005;42(5):987-1000
24. Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol 2015
25. Eguchi Y, Eguchi T, Mizuta T, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 2006;41(5):462-9
26. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 2011;23(2):192-202
27. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 2013;25(2):210-16
28. Lee JM, Kim HC, Cho HM, et al. Association between serum uric acid level and metabolic syndrome. J Prev Med Pub Health 2012;45(3):181-7
29. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120(5):442-7
30. Mangge H, Zelzer S, Puerstner P, et al. Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity (Silver Spring) 2013;21(1):E71-7
31. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. Jama 1991;266(21):3008-11
32. Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268(1 Pt 1):E1-5
33. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9(8):746-52
34. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005;1(2):80-6
35. Roy D, Perreault M, Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol 1998;274(4 Pt 1):E692-9
36. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC public health 2004;4:9
37. Shih MH, Lazo M, Liu SH, et al. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc 2015;114(4):314-20
38. Xu C, Yu C, Xu L, et al. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: A prospective observational study. PloS One 2010;5(7):e11578
39. Xu CF, Yu CH, Xu L, et al. Hypouricemic therapy: A novel potential therapeutic option for nonalcoholic fatty liver disease. Hepatology 2010;52(5):1865-6
40. Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002;34(3):204-11
41. Li Y, Xu C, Yu C, et al. Association of serum uric acid level with non-alcoholic fatty liver disease: A cross-sectional study. J Hepatol 2009;50(5):1029-34
42. Wu SJ, Zhu GQ, Ye BZ, et al. Association between sex-specific serum uric Acid and non-alcoholic Fatty liver disease in chinese adults: A large population-based study. Medicine 2015;94(17):e802
43. Liu PJ, Ma F, Lou HP, et al. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. Climacteric : The journal of the International Menopause Society 2014;17(6):692-9
44. Lee YJ, Lee HR, Lee JH, et al. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clinical chemistry and laboratory medicine : CCLM/FESCC 2010;48(2):175-80
45. Lee JW, Cho YK, Ryan M, et al. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: A 5-year retrospective cohort study. Gut and liver 2010;4(3):378-83
46. Baba T, Amasaki Y, Soda M, et al. Fatty liver and uric acid levels predict incident coronary heart disease but not stroke among atomic bomb survivors in Nagasaki. Hypertens Res 2007;30(9):823-9
47. Cardoso AS, Gonzaga NC, Medeiros CC, Carvalho DF. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. J Pediatr (Rio J) 2013;89(4):412-18
48. Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014;49(11):1477-84
49. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006;44(3):581-91
50. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011;60(4):1258-69
51. Zhang X, Zhang JH, Chen XY, et al. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation. Antioxidants & redox signaling 2015;22(10):848-70
52. Wang W, Wang C, Ding XQ, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 2013;169(6):1352-71
53. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012;57(3):642-54
54. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009;50(5):1421-30
55. Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Laboratory investigation; a journal of technical methods and pathology 2014;94(10):1114-25
56. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009;11(5):444-52
57. Ilkun O, Boudina S. Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. Curr Pharm Des 2013;19(27):4806-17
58. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger? Science 2010;327(5963):296-300
59. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21(5):504-11
60. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27(10):1174-81
61. Ruggiero C, Cherubini A, Miller E 3rd, et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 2007;100(1):115-21
62. Ives A, Nomura J, Martinon F, et al. Xanthine oxidoreductase regulates macrophage IL1beta secretion upon NLRP3 inflammasome activation. Nat Commun 2015;6:6555
63. Xu C, Wan X, Xu L, et al. Xanthine oxidase in nonalcoholic fatty liver disease and hyperuricemia: One stone hits two birds. J Hepatol 2015
64. Nakatsu Y, Seno Y, Kushiyama A, et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointestinal Liver Physiol 2015;309(1):G42-51
65. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PloS One 2012;7(10):e47948
66. Filippatos TD, Elisaf MS. Combination drug treatment in patients with nonalcoholic fatty liver disease. World J Hepatol 2010;2(4):139-42
67. Kim HK, Park JY, Lee KU, et al. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci 2009;337(2):98-102
68. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6(12):1396-402
69. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6(9):998-1003
70. Matafome P, Louro T, Rodrigues L, et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011;27(1):54-62
71. Khanna PP, FitzGerald J. Evolution of management of gout: A comparison of recent guidelines. Curr Opin Rheumatol 2015;27(2):139-46
72. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol 2014;10(5):271-83
73. Frampton JE. Febuxostat: A review of its use in the treatment of hyperuricaemia in patients with gout. Drugs 2015;75(4):427-38
74. Abeles AM. Febuxostat hypersensitivity. J Rheumatol 2012;39(3):659
75. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68(6):892-7
76. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of uratelowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68(1):51-6
77. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31(8):643-65
78. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Jama 2011;306(7):711-20
79. Zhu X, Chen J, Han F, et al. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. Transplant Proc 2009;41(9):3736-42
80. Huang HY, Appel LJ, Choi MJ, et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum 2005;52(6):1843-7
81. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a doubleblind, placebo-controlled trial. Metabolism 1988;37(3):217-20
82. Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am 2014;40(2):375-87
83. Gregoire FM, Zhang F, Clarke HJ, et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol 2009;23(7):975-88
84. Diaz-Torne C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 2015;27(2):164-9